Formulation and evaluation of liquisolid compact of azithromycin dihydrate

Year 2019, Volume: 23 Issue: 6, 1022 - 1032, 27.06.2025

Sayani Bhattacharyya , Imran Pasha Anisha Verma Ridhi Kothapalli Fajas Jafar Kavya Hr

https://izlik.org/JA52ZZ78ZE

Abstract

Azithromycin dihydrate is a macrolide antibiotic and belongs to BCS class II drugs. The present study aims at the preparation of liquisolid compact of azithromycin dihydrate with an aim to improve the solubility of the drug. The liquid solid system uses a nonvolatile solvent to dissolve the drug. The solution or suspension of drug is converted into a free flowing dry and compressible powder in an admixture of coating and carrier material calculated mathematically. In this study Avicel PH102 and Aerosil 200 were used as carrier and coating material respectively. Propylene glycol was used as the nonvolatile solvent. Using different excipient ratio six formulations were made and evaluated for flowability and compressibility characteristics. Drug excipient interaction study was performed through Fourier transform infrared spectroscopy (FTIR). The formulations were subjected to statistical analysis. Optimization of the formulation was done through JMP V8.0 software. The optimized formulations were evaluated for flowability, compressibility study, thermal analysis by differential scanning calorimetry (DSC) and comparative dissolution study with pure drug. The optimized formulations showed a good flow property and compression characteristics. The FTIR study revealed no physical interaction of the drug with the excipient. The DSC thermograms proved the conversion of crystalline structure of the drug into its amorphous form. The comparative dissolution study of the optimized formulations with the pure drug revealed significant improvement of solubility of azithromycin dihydrate in liquid solid compact. Therefore, it can be concluded that a free flowing, non-adherent, dry and compressible powder of azithromycin dihydrate can be prepared using liquid solid compact technology.

Keywords

Azithromycin dihydrate , liquisolid compact , solubility , optimization , DSC

References

• [1] Pawar JD, Jagtap RS, Doijad RC, Pol SV, Desai JR, Jadhav VV, Jagtap SR. Liquisolid compacts: A promising approach for solubility enhancement. J Drug Deliv Ther. 2017; 7(4): 6-11. [CrossRef]
• [2] Anand DS, Malavi RB, Vishal DG, Pooja MK. Liquisolid technique: a review. Int J Pharm Sci Res. 2017; 8(7): 2768-2775. [CrossRef]
• [3] Jignesh S, Dhiren D, Ghanshyam P, Bhavin B, Upendra P, Darshan K. Liquisolid compacts: A novel approach to enhance the dissolution. Res J Pharm Tech. 2013; 6(3): 313-320.
• [4] Patil DS, Magar D, Saudagar RB. Liquisolid technology: technique for formulation with enhanced bioavailability. World J Pharm Pharm Sci. 2013; 3(1): 368-387.
• [5] Pusuluri DLS, Konkipudi VS, Brahmaih B, Pasam VR. Review on liquisolid compact technology. World J Pharm Res. 2015; 4(2): 293-306.
• [6] Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin— review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother. 1996; 37(1): 1–8.
• [7] Idkaidek NM, Najib MN. Salem I, Jilani J. Physiologically Based IVIVC of Azithromycin. Am J Pharmacol Sci. 2014; 2(6): 100–102. [CrossRef]
• [8] Govil S, Sadhna K, Sandeep A. Formulation and characterization of liquisolid compacts of valsartan. J Pham Res. 2012; 5(8): 4158-4162.
• [9] Sultana S, Aryane MS, Hussain F, Fatima A. Degradation studies of azithromycin and its spectrophotometric determination in pharmaceutical dosage form. Pak J Pharm Sci. 2006; 19(2): 94-98.
• [10] Chella N, Shastria N, Rama RT. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharmaceutica Sinica B. 2012; 2(5): 502–508. [CrossRef]
• [11] Poluri K, Suvarnala S, Puttugunta S, Govada KB, Pinnamraju DN. Formulation Development and evaluation of fast disintegrating tablets of Lamotrigine using liqui-solid technique. Int J Pharm Investig. 2012; 4(4): 207–214.
• [12] Spireas S, Bolton M. Liquisolid systems and methods of preparing same. 1999, U.S. Patent 5,968,550.
• [13] Spireas S. Liquisolid systems and methods of preparing same. 2002, U.S. Patent 6,423,339 B1
• [14] Patel DS, Pipaliya RM, Surti N. Liquisolid Tablets for dissolution enhancement of a hypolipidemic drug. Indian J Pharm Sci. 2015; 77(3): 290-298.
• [15] Soujanya B, Srujankumar M, Subhramanyam KV, Subhrajit M. Enhancement of solubility of efavirenz by liquisolid compact technique. Int J Innov Pharm Sci Res. 2013; 1(3): 347-359.
• [16] Lakshmi PK, Srinivas C, Kalpana B. Preparation and comparative evaluation of liquisolid compacts and solid dispersions of Valsartan. S J Pharm Sci. 2011; 4(2): 48-57.
• [17] Zainab EJ. Formulation and evaluation of furosemide liquisolid compact. Int J App Pharm. 2017; 99(6): 39-48. [CrossRef]
• [18] Shailesh TP, Hitesh HB, Dashrath MP, Suresh KD, Chhaganbhai NP. Formulation and evaluation of liquisolid compacts for olmesartan medoxomil. J Drug Del. 2013; Article ID 870579: 1-9. [CrossRef]